Odense University Hospital
Odense, 5230, Denmark
Location status: Recruiting
Location contact
Katrine Pilely
CONTACT
NCT Number: NCT05266092
Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year). Cardiovascular complications and bloodstream infections (BSIs) account for the vast majority of deaths in HD patients. In Denmark, BSIs occur in 14% of HD patients per year and is most frequently caused by Staphylococcus aureus (44%). The most frequent infectious complication is endocarditis that has fatal outcomes in ≈50% of the cases. Overall, 10% of HD patients die within 30 days after a positive blood culture for S. aureus. This project aims to answer key questions regarding HD patients' decreased ability to fight S. aureus BSIs and in particular the potential exacerbating effect of HD. We hypothesize that HD patients' blood is significantly compromised by the process of HD, to an extend that lowers immunoactivity against S. aureus. Moreover, we hypothesize, that contact activation promotes the coagulability of blood thus promoting biofilm formation by S. aureus which increases the overall risk of BSI. We will test these hypotheses by collecting blood and analyzing the inflammation and coagulation status in plasma samples from participants before and after HD. We will compare the level of the inflammatory markers in plasma from participants undergoing HD (n=180) to the level in plasma samples from three control groups: healthy volunteers (n=120), participants with renal disease not in dialysis (n=60) and participants undergoing peritoneal dialysis (n=40).
Interested in participating?
Request Info18 year and older
All sexes
Observational
Odense, 5230, Denmark
Location status: Recruiting
Katrine Pilely
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Participants with chronic kidney disease undergoing hemodialysis Inclusion criteria
Exclusion criteria
Participants with chronic kidney disease, not in dialysis Inclusion criteria
Exclusion criteria
Participants with chronic kidney disease undergoing peritoneal dialysis Inclusion criteria
Exclusion criteria
Healthy volunteers Inclusion criteria
Exclusion criteria
Observational study
Time frame: At enrollment
cHK is the final activation product of the contact activation system
Contact information is provided by the study sponsor or research team.
Odense University Hospital
Other
Activation of the Contact System and the Immune System in Patients With Chronic Kidney
Acronym: AKIM-CKD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06660277
Chronic Disease, Chronic Kidney Disease Requiring Chronic Dialysis
London, Ontario, Canada
View Trial DetailsNCT04125537
Chronic Disease, Chronic Kidney Disease Requiring Chronic Dialysis
Arvada, Colorado, United States
View Trial DetailsNCT04032613
Chronic Disease, Chronic Kidney Disease
Danville, Pennsylvania, United States
View Trial DetailsNCT07710183
Chronic Disease, Chronic Kidney Disease Requiring Chronic Dialysis
Baghdad, Karkh, Iraq
View Trial Details